Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) treatment includes the use of the anti-CD20 monoclonal antibody rituximab (RTX). RTX acts through Fcγ-receptors (FCGR) on effector natural killer cells and macrophages and it can be administered effectively in RA and in lymphomas. Based on the results of in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pál, Ildikó, Szamosi, Szilvia, Hodosi, Katalin, Szekanecz, Zoltan, Váróczy, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687551/
https://www.ncbi.nlm.nih.gov/pubmed/29177079
http://dx.doi.org/10.1136/rmdopen-2017-000485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687551/
https://www.ncbi.nlm.nih.gov/pubmed/29177079
http://dx.doi.org/10.1136/rmdopen-2017-000485

Ejemplares similares